Pfizer is rated a buy not because it is deeply undervalued now, but due to a disconnect between management's optimistic long-term growth outlook and the market's flat earnings expectations. While consensus models predict a revenue and earnings decline after 2026, Pfizer's core $13 billion product base is growing at over 20% annually, and the Vyndamax settlement guarantees $2–3 billion in yearly revenue through 2031. Management forecasts a high single-digit revenue growth rate from 2028 to 2033, implying revenues of $21–26 billion by 2033, which surpasses even the most optimistic analyst estimates. The stock's downside risk appears priced in, and potential gains depend on upward revisions to long-term earnings rather than multiple expansions.
Pfizer's optimistic long-term outlook contrasts with the market's current pricing, as seen in its steady performance on Pluang. As of September 26, 2026, at 14:21 WIB, Pfizer trades at USD 28.67 with a 1-day gain of 0.84%. The stock shows strong investor interest, with 70% of Pluang orders being buys, and it offers a notable dividend yield of 6.05%.
Pfizer faces significant revenue declines as key drug patents expire, but aims to maintain stable earnings through 2028 with a new drug pipeline and cost-saving measures targeting up to $4 billion in savings. The company projects 2026 revenues of $61...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance. Pfizer showed modest growth with a 5.4% revenue increase in Q1 2026, focusing on oncology and obesity ...
AT&T, Verizon, and Pfizer are three large dividend-paying stocks trading below $50, making them accessible for investors with under $1,000 per stock. Together, a $3,000 investment in these stocks could generate approximately $166.80 in annual passive...
Pfizer has been upgraded to a buy rating due to its attractive low valuation, robust free cash flow, and a high dividend yield of 6.2%. The company reported better-than-expected Q2 results and raised its full-year revenue guidance, supported by progr...
Pfizer reported a strong quarterly performance, raising its revenue guidance to $61.5 billion driven by a robust non-COVID product portfolio and recent acquisitions. The company is implementing operational efficiency programs aimed at saving $9.7 bil...
